U.S. Patent for human telomerase catalytic subunit. I printed what I thought was the 1st page of this and 346 pages later the printer stopped. It will take a while to read all this. But this should be good news for Geron.
Geron's low for the week was $1.38 on Dec 23 and Dec 29. The high for the week was $1.50 Dec 30. The avg. volume is slowly going up, the share price should move higher. Three month avg. 1,567,610 shares, ten days avg 1,656,220 shares, the short week avg. volume was 1,925760 shares.
Year end selling for tax lose is over, Geron should start moving up in price.
Good luck in this rigged casino,
Friday, December 30, 2011
Tuesday, December 27, 2011
Geron now a bargain Buy
Geron Now a Bargain Buy by Jeremy Richards on Seeking Alpha. This the last part of article.
The average price target by analysts is now $4 a share.
In the last 6 months, GERN's stock price has dropped from the $4 level down to a recent low of $1.35. In my opinion, the current stock price of $1.41 represents a bargain buy considering GERN has a $150M cash on hand and a current market-cap of $185M and trading just above its book value of $1.34. I believe buying the stock under its 50 day moving average of $1.73 is a bargain. I would be a seller around the 200 day moving average of $2.69.
GERN insiders currently hold 10.3 million shares or 7.8% of outstanding shares. Director Thomas Kiley purchased 64,275 shares on November 22nd, 2011. This is in addition to the 50,000 shares that he purchased at $2.03 on Oct 5, 2011, increasing his holdings to 314,059 shares. The total 114,275 share purchase by Mr. Kiley is significant given that it is the only insider purchase in at least the last eight years. The share purchase is also a sign of confidence in the company.
The Market liked the story, Geron was up 3 whole cent, on over 2.5 milion shares, three month avg is 1,543,416 shares. I'm still waiting for some real good news to take the price to $2.00. Then will sell some and sell some covered called.
Good luck in this rigged casino,
The average price target by analysts is now $4 a share.
In the last 6 months, GERN's stock price has dropped from the $4 level down to a recent low of $1.35. In my opinion, the current stock price of $1.41 represents a bargain buy considering GERN has a $150M cash on hand and a current market-cap of $185M and trading just above its book value of $1.34. I believe buying the stock under its 50 day moving average of $1.73 is a bargain. I would be a seller around the 200 day moving average of $2.69.
GERN insiders currently hold 10.3 million shares or 7.8% of outstanding shares. Director Thomas Kiley purchased 64,275 shares on November 22nd, 2011. This is in addition to the 50,000 shares that he purchased at $2.03 on Oct 5, 2011, increasing his holdings to 314,059 shares. The total 114,275 share purchase by Mr. Kiley is significant given that it is the only insider purchase in at least the last eight years. The share purchase is also a sign of confidence in the company.
The Market liked the story, Geron was up 3 whole cent, on over 2.5 milion shares, three month avg is 1,543,416 shares. I'm still waiting for some real good news to take the price to $2.00. Then will sell some and sell some covered called.
Good luck in this rigged casino,
Monday, December 26, 2011
Geron road to profitability
The long term investor will need a strong stomach, no scardy cats. The biotech investors will not like waiting till Dec 2012 for good results, if any. I have a bad feeling the share price will go below a dollar in the 1st half of 2012.
Here's a few things that may keep the share price above a dollar.
There is a chance of a buy-out or partership with a company with deep pockets.
The brain treatment for cancer GRN1005, results 1st quarter of 2013
The four Phase II trials that end Dec 2012 and results will be in same month.
Good luck in this rigged casino,
Here's a few things that may keep the share price above a dollar.
There is a chance of a buy-out or partership with a company with deep pockets.
The brain treatment for cancer GRN1005, results 1st quarter of 2013
The four Phase II trials that end Dec 2012 and results will be in same month.
Good luck in this rigged casino,
Friday, December 23, 2011
Geron passes out Christmas Bonuses $600,000 split four ways
That's right, four Geron execs split $600,00 in cash bonuses. Geron in November said it would cut 66 jobs and halt its stem cells R&D program to concentrate on its portfolio of experimental cancer treatments. It's a little upsetting, bonuses for the top execs, while cutting jobs and halting its stem cell program. It's not like David Greenwood who makes $618,000 a year needs a $235,800 bonus or Dr. Stephen Kelsey who makes $595,000 a year and his bonus was $156,600. Melissa Kelly Behrs bonus was $107,500 and Jane Lebkowski received $107,200. I think stock options, based performce, are the right type of bonuses. No product or money coming in, no bonuses simple.
I sold 900 shares at $1.42, made a little money. The high for the week was $1.51 on Monday Dec. 19th and the low was $1.35 on Wednesday Dec. 21st. The avg. five day volume was 1,601,720 shares the three month avg was 1,543,410. Maybe we are at the bottom. If the volume and price start to slowly move up we should hit $2.00 by the end of Feb 2012.
Geron this month started two Phase II trials one evaluating its drug GRN1005 in lung ccancer that has spread to the brain. The other using the same drug to treat breast cancer that has spread to the brain. Results some time early in 2013.
Good luck in this rigged casino,
I sold 900 shares at $1.42, made a little money. The high for the week was $1.51 on Monday Dec. 19th and the low was $1.35 on Wednesday Dec. 21st. The avg. five day volume was 1,601,720 shares the three month avg was 1,543,410. Maybe we are at the bottom. If the volume and price start to slowly move up we should hit $2.00 by the end of Feb 2012.
Geron this month started two Phase II trials one evaluating its drug GRN1005 in lung ccancer that has spread to the brain. The other using the same drug to treat breast cancer that has spread to the brain. Results some time early in 2013.
Good luck in this rigged casino,
Thursday, December 22, 2011
Phase 2 for GRN1005 started
MENLO PARK, Calif., December 22, 2011 - Geron Corporation (Nasdaq: GERN - News) today announced the initiation of GRABM-L (GRN1005 Against Brain Metastases - Lung cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from non-small cell lung cancer (NSCLC). GRN1005 is the company`s lead LRP-directed peptide-drug conjugate (LRP-directed PDC) and consists of the cytotoxic drug paclitaxel linked to a peptide (Angiopep-2) that targets the LRP receptor to cross the blood-brain barrier (BBB) and to target tumors in the brain.
"With the treatment of the first patient in the GRABM-L study, we have initiated both of the planned Phase 2 clinical trials of GRN1005 in patients with cancer metastases in the brain, a significant unmet medical need for which there are currently no approved drug therapies," said Stephen M. Kelsey, M.D., Geron`s Executive Vice President, Head of R&D and Chief Medical Officer. "We have been encouraged by the preliminary evidence of anti-tumor activity against brain metastases observed in the Phase 1 study of GRN1005, and we hope to confirm these results in our Phase 2 trials."
Phase 2 Clinical Trial Design (GRABM-L)
The purpose of the Phase 2 study is to assess the efficacy, safety and tolerability of GRN1005 in patients with brain metastases from NSCLC. The trial plans to enroll 50 patients.
GRN1005 will be administered at a dose of 650 mg/m2 by intravenous (IV) infusion every three weeks. The primary efficacy endpoint for the trial is overall (intra-cranial and extra-cranial disease) objective response rate. Key secondary endpoints include duration of overall objective response, duration of overall progression-free survival and six month overall survival.
Rationale for the Study
Cancer in the brain, particularly metastases, currently represents a significant unmet medical need, because drugs that might be effective against these tumor types are not able to efficiently cross the blood-brain barrier and enter the tumor. Preclinical and Phase 1 data indicate that GRN1005 not only transports paclitaxel into tumors inside the brain through LRP1-mediated transport, but also has activity against tumors outside the brain.
Data on safety and tolerability, and preliminary evidence of anti-tumor activity of GRN1005 were documented in two separate Phase 1 multi-center, open-label, dose escalation clinical trials, conducted by Angiochem, Inc., in patients with heavily pre-treated progressing, advance-stage solid tumors and brain metastases (n=56; including NSCLC) and in patients with recurrent or progressive malignant glioma (n=63). Final data were presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in November.
In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m2 of GRN1005 administered as single-agent therapy once every three weeks. The anti-tumor activity was observed against metastases inside the brain as well as in organs outside of the brain, such as the liver, lung and lymph nodes. Among the patients who responded to treatment with GRN1005, were patients who had previously progressed on taxane therapy.
Geron`s clinical development plan for GRN1005 includes two Phase 2 clinical trials in patients with brain metastases arising from either breast cancer (GRABM-B) or non-small cell lung cancer (GRABM-L). Top-line data from both studies are expected to be available by the end of the second quarter of 2013.
About Brain Metastases
Metastases in the brain arising from primary tumors in other organs are associated with considerable morbidity and mortality. Lung cancer is the most common cause of metastases to the brain, followed by breast cancer.
There are currently no approved drug therapies for the treatment of brain metastases. Brain metastases are very difficult to treat because most drugs, including oncology drugs, such as paclitaxel, that are effective against lung cancer, cannot reach the brain at levels that are clinically therapeutic. Drugs are unable to reach the brain because of the blood-brain-barrier (BBB). Transport across the BBB and into tumors is critical for developing effective treatments for cancers in the brain.
About GRN1005
GRN1005 (previously known as ANG1005) is an LRP-directed peptide-drug conjugate (LRP-directed PDC) being developed for the treatment of cancers in the brain. GRN1005 is designed to deliver cytotoxic drug across the BBB and into tumors by exploiting a native mechanism by which essential substances, such as lipids and hormones, are actively transported into the brain through receptors. GRN1005 is comprised of three molecules of paclitaxel linked to a proprietary 19 amino acid peptide (Angiopep-2) that is designed to target the lipoprotein receptor-related protein 1 (LRP1), one of the most highly expressed receptors on the surface of the BBB. Binding to LRP1 facilitates receptor-mediated transport, or transcytosis, across the BBB into the brain tissue. LRP1 is also up-regulated in many tumors, therefore once in the brain, GRN1005 may gain entry into tumor cells using the same receptor by a process known as endocytosis. GRN1005 is a prodrug, which becomes activated in cells after it is cleaved by esterases to release active paclitaxel from the peptide.
This is good news, the market didn't care. Geron up only 2 cent and volume was 1,404,723 shares, nothing great. Geron needs 10 patients out of the 50 to show improvement.
Good luck in this rigged casino,
"With the treatment of the first patient in the GRABM-L study, we have initiated both of the planned Phase 2 clinical trials of GRN1005 in patients with cancer metastases in the brain, a significant unmet medical need for which there are currently no approved drug therapies," said Stephen M. Kelsey, M.D., Geron`s Executive Vice President, Head of R&D and Chief Medical Officer. "We have been encouraged by the preliminary evidence of anti-tumor activity against brain metastases observed in the Phase 1 study of GRN1005, and we hope to confirm these results in our Phase 2 trials."
Phase 2 Clinical Trial Design (GRABM-L)
The purpose of the Phase 2 study is to assess the efficacy, safety and tolerability of GRN1005 in patients with brain metastases from NSCLC. The trial plans to enroll 50 patients.
GRN1005 will be administered at a dose of 650 mg/m2 by intravenous (IV) infusion every three weeks. The primary efficacy endpoint for the trial is overall (intra-cranial and extra-cranial disease) objective response rate. Key secondary endpoints include duration of overall objective response, duration of overall progression-free survival and six month overall survival.
Rationale for the Study
Cancer in the brain, particularly metastases, currently represents a significant unmet medical need, because drugs that might be effective against these tumor types are not able to efficiently cross the blood-brain barrier and enter the tumor. Preclinical and Phase 1 data indicate that GRN1005 not only transports paclitaxel into tumors inside the brain through LRP1-mediated transport, but also has activity against tumors outside the brain.
Data on safety and tolerability, and preliminary evidence of anti-tumor activity of GRN1005 were documented in two separate Phase 1 multi-center, open-label, dose escalation clinical trials, conducted by Angiochem, Inc., in patients with heavily pre-treated progressing, advance-stage solid tumors and brain metastases (n=56; including NSCLC) and in patients with recurrent or progressive malignant glioma (n=63). Final data were presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in November.
In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m2 of GRN1005 administered as single-agent therapy once every three weeks. The anti-tumor activity was observed against metastases inside the brain as well as in organs outside of the brain, such as the liver, lung and lymph nodes. Among the patients who responded to treatment with GRN1005, were patients who had previously progressed on taxane therapy.
Geron`s clinical development plan for GRN1005 includes two Phase 2 clinical trials in patients with brain metastases arising from either breast cancer (GRABM-B) or non-small cell lung cancer (GRABM-L). Top-line data from both studies are expected to be available by the end of the second quarter of 2013.
About Brain Metastases
Metastases in the brain arising from primary tumors in other organs are associated with considerable morbidity and mortality. Lung cancer is the most common cause of metastases to the brain, followed by breast cancer.
There are currently no approved drug therapies for the treatment of brain metastases. Brain metastases are very difficult to treat because most drugs, including oncology drugs, such as paclitaxel, that are effective against lung cancer, cannot reach the brain at levels that are clinically therapeutic. Drugs are unable to reach the brain because of the blood-brain-barrier (BBB). Transport across the BBB and into tumors is critical for developing effective treatments for cancers in the brain.
About GRN1005
GRN1005 (previously known as ANG1005) is an LRP-directed peptide-drug conjugate (LRP-directed PDC) being developed for the treatment of cancers in the brain. GRN1005 is designed to deliver cytotoxic drug across the BBB and into tumors by exploiting a native mechanism by which essential substances, such as lipids and hormones, are actively transported into the brain through receptors. GRN1005 is comprised of three molecules of paclitaxel linked to a proprietary 19 amino acid peptide (Angiopep-2) that is designed to target the lipoprotein receptor-related protein 1 (LRP1), one of the most highly expressed receptors on the surface of the BBB. Binding to LRP1 facilitates receptor-mediated transport, or transcytosis, across the BBB into the brain tissue. LRP1 is also up-regulated in many tumors, therefore once in the brain, GRN1005 may gain entry into tumor cells using the same receptor by a process known as endocytosis. GRN1005 is a prodrug, which becomes activated in cells after it is cleaved by esterases to release active paclitaxel from the peptide.
This is good news, the market didn't care. Geron up only 2 cent and volume was 1,404,723 shares, nothing great. Geron needs 10 patients out of the 50 to show improvement.
Good luck in this rigged casino,
Wednesday, December 21, 2011
Added more at 1.35
At $1.35 I added more shares. Just for a quick trade, any move up above 1.45 and it's sell. Chip the new CEO will made a deal soon on the stem cells, I hope.
Good luck in this rigged casino,
Good luck in this rigged casino,
Friday, December 16, 2011
Geron volume 5 million today
Volume was 5,494,100 today the avg ten day volume is 1,101,076 shares. Why the big increase on Friday. I checked the message board and no one knows. Alot of guesses.
The share price is worrying me. It could go below a dollar. Waiting for a parnter. Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.
Good luck in this rigged casino,
The share price is worrying me. It could go below a dollar. Waiting for a parnter. Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.
Good luck in this rigged casino,
Wednesday, December 14, 2011
Geron Patient #5 Katie Sharify
Stem cell trial halted, but 23-year-old recipient still has hope
http://www.mercurynews.com/bay-area-news...
Stem cell clinical trials were still under way last month when Katie Sharify's car careened off Highway 5, ejecting her through the back window and paralyzing her from the waist down.
Stanford and Valley Medical Center doctors considered Sharify an ideal candidate to test whether an injection of embryonic cells was safe and could help her regain any sensation.
But just two days before she was scheduled to receive the treatment, the Menlo Park company leading the trials canceled the program. Sharify's doctors injected her anyway, giving her a chance, no matter how small, that two million stem cells creeping up her damaged spine could make a difference.On Tuesday, as Sharify, 23, sat in her wheelchair at Santa Clara County's Valley Medical Center, she discussed her mixed feelings about being the fifth -- and for now, the last -- patient in the United States to receive the experimental treatment for paralysis victims.
Words come easily to Sharify; she had been a communications major at USC and a 2006 graduate of Amador Valley High School in Pleasanton, where she had been a member of a future business leaders club.
"I want someone somewhere to see me," Sharify said. "Maybe there's a head of a big company who sees this and says, 'we should help this girl.' "
Good luck in this rigged casino,
http://www.mercurynews.com/bay-area-news...
Stem cell clinical trials were still under way last month when Katie Sharify's car careened off Highway 5, ejecting her through the back window and paralyzing her from the waist down.
Stanford and Valley Medical Center doctors considered Sharify an ideal candidate to test whether an injection of embryonic cells was safe and could help her regain any sensation.
But just two days before she was scheduled to receive the treatment, the Menlo Park company leading the trials canceled the program. Sharify's doctors injected her anyway, giving her a chance, no matter how small, that two million stem cells creeping up her damaged spine could make a difference.On Tuesday, as Sharify, 23, sat in her wheelchair at Santa Clara County's Valley Medical Center, she discussed her mixed feelings about being the fifth -- and for now, the last -- patient in the United States to receive the experimental treatment for paralysis victims.
Words come easily to Sharify; she had been a communications major at USC and a 2006 graduate of Amador Valley High School in Pleasanton, where she had been a member of a future business leaders club.
"I want someone somewhere to see me," Sharify said. "Maybe there's a head of a big company who sees this and says, 'we should help this girl.' "
Good luck in this rigged casino,
Monday, December 12, 2011
Geron Initiates Phase 2 of GRN1005 in Brain Metastases From Breast Cancer
Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer
Great news! If Geron can get good results, it will be fast tracked. In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m(2) of GRN1005 administered as single-agent therapy once every three weeks.
Good luck in this rigged casino,
Great news! If Geron can get good results, it will be fast tracked. In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m(2) of GRN1005 administered as single-agent therapy once every three weeks.
Good luck in this rigged casino,
Sunday, December 11, 2011
No news for Geron
Geron volume was only 814,240 shares over five days. Ten day avg. volume was 1,042,103 and three months was 1,517,420 shares. The high for the week was $1.77 on Monday the low $1.55 on Thursday.
Need partners.
Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.
The share price is worrying me. It could go below a dollar. Waiting for a parnter. Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.
Good luck in this rigged casino,
Need partners.
Celgene, Pfizer and Teva Pharm. are in stem cell research, small time. Partnering with Geron would make them big time and they have the money to fund the research.
The share price is worrying me. It could go below a dollar. Waiting for a parnter. Good news from the four Phase II trials will raise the share price. If by the end of 2012 the results from the 4 Phase II trials are anything but outstanding, I will sell most of my shares. For now any move over $2, I will sell some shares and sell a few covered calls.
I put a lot of time and money into Geron, believing [and still do] in the stem cell program, now there is very little reason for me to hold a large position in this company. Will cut my position by at least half.
Good luck in this rigged casino,
Tuesday, December 6, 2011
No news is the story for Geron
No news on the patent case against Viacyte. No news on anyone buying Geron's stem cell program. No news on partnering. No increase in volume or share price.
Just wait and see if "Chip" the new CEO can work some magic.
Good luck in this rigged casino,
Just wait and see if "Chip" the new CEO can work some magic.
Good luck in this rigged casino,
Thursday, December 1, 2011
Geron slowly moving up, why
The patent case against Viacyte is coming to a end. We should have an announcement Thursday or early next week. Hoping it's good news for longs. Geron share price is $1.76 up 9 cent. at 1:36PM.
Good luck in this riggeed casino,
Good luck in this riggeed casino,
Subscribe to:
Posts (Atom)